Terazosin effect on the treatment of urinary tract obstruction symptoms in women

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221223056903N1

Enrollment

110

Registered

2023-04-15

Start date

2023-02-20

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary obstruction symptoms in women.

Interventions

Intervention group:A total of 110 people were randomly selected from those who referred to the Urology Clinic of Vasi Hospital and private practices with complaints of urinary obstruction symptoms and

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All women over the age of 18 years who complain of obstructive symptoms and go to the urology treatment of Vaesi Hospital or a private urology office are included in the study.

Exclusion criteria

Exclusion criteria: causing drug side effects such as dizziness or orthostatic hypotension ???Lack of informed consent to participate in the study

Design outcomes

Primary

Measure	Time frame
Urinary obstruction symptoms in women. Timepoint: Measuring the average urine volume with uroflowmetry and completing the International Prostate Symptom Scoring Questionnaire (IPSS) at the beginning of the study and one month after taking the drug. Method of measurement: Uroflowmetry and International Prostate Symptom Scoring Questionnaire (IPSS) questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Shakeriasil

Sabzevar University of Medical Sciences

shakeriA94@medsab.ac.ir+98 51 4423 5138

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026